Gabapentin Dosing for Postherpetic Neuralgia

Initial Dosing and Titration

• The target maintenance dose of gabapentin for postherpetic neuralgia is typically reached by titrating up to 1800 mg/day, with a maximum of 3600 mg/day in three divided doses if needed, as demonstrated in clinical trials 1, 2

Target and Maximum Dosing

• Clinical trials have shown that doses above 1800 mg/day do not provide additional benefit for pain control, but may increase adverse effects 1

Duration of Adequate Trial

• An adequate trial of gabapentin requires 3-8 weeks for titration plus 2 weeks at maximum tolerated dose, which can take 2 months or more to properly assess efficacy 1, 2

Dosing Intervals and Pharmacokinetic Considerations

• Gabapentin has nonlinear pharmacokinetics due to saturable absorption in the proximal small intestine, necessitating divided dosing throughout the day 1, 2

Renal Dose Adjustments

• Dosage reduction is mandatory in renal insufficiency, with specific adjustments based on creatinine clearance values, such as 200-700 mg/day for patients with creatinine clearance of 15-29 mL/min 1, 2, 3

Special Population Considerations

• Elderly patients require lower starting doses and slower titration due to decreased renal function and increased risk of adverse effects, as recommended by the Mayo Clinic Proceedings 1, 2, 3, 4, 5

Clinical Efficacy Evidence

• The American College of Physicians recommends gabapentin as first-line oral pharmacological treatment for postherpetic neuralgia, based on evidence from clinical trials 6

Critical Pitfalls to Avoid

• The American College of Physicians and Mayo Clinic Proceedings agree that undertitration and premature assessment of efficacy should be avoided, and that renal adjustment is crucial to prevent toxicity 1, 6